Longeveron (NASDAQ:LGVN) Cut to “Hold” at Maxim Group

Maxim Group cut shares of Longeveron (NASDAQ:LGVN – Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday, MarketBeat reports.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a report on Tuesday, April 21st. HC Wainwright lowered their price target on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, May 4th. Finally, Wall Street Zen lowered shares of Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.50.

Get Longeveron alerts:

Read Our Latest Analysis on LGVN

Longeveron Stock Up 0.7%

Shares of LGVN stock opened at $0.76 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.33 and a current ratio of 1.33. The firm’s 50-day moving average is $0.93 and its 200-day moving average is $0.72. The stock has a market cap of $17.57 million, a price-to-earnings ratio of -0.59 and a beta of -0.31. Longeveron has a 52-week low of $0.48 and a 52-week high of $1.80.

Longeveron (NASDAQ:LGVN – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.33 million. Longeveron had a negative net margin of 1,893.58% and a negative return on equity of 199.79%. Sell-side analysts predict that Longeveron will post -0.7 EPS for the current year.

Institutional Trading of Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd purchased a new position in shares of Longeveron Inc. (NASDAQ:LGVN – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron at the end of the most recent quarter. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

(Get Free Report)

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.

Featured Stories

• Five stocks we like better than Longeveron
• D-Wave Earnings Looked Weak, But Investors May Be Missing This
• Nebius Upside Expands as AI Feedback Loop Intensifies
• Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
• Plug Power Flips The Switch On Profitability

Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.